As outlined bei Keiji UEHARA, Director of the Nuclear Medicine Research Institute of Kyowa Hakko Kirin, in a presentation at the 4th Annual Meeting of the Japan Society of Nucleic Acid Science, the company has developed such technology based on a modified sugar chain ligand targeting CD206.

Nikkei Biotech news release, July 23, 2018